Relationship between the Finnish Diabetes Risk Score (FINDRISC), vitamin D levels, and insulin resistance in obese subjects

Published: Primary Care Diabetes
Date:
Authors: Marcos M Lima-Martínez 1 , Carlos Arrau 2 , Saimar Jerez 2 , Mariela Paoli 3 , Juan P González-Rivas 4 , Ramfis Nieto-Martínez 5 , Gianluca Iacobellis 6
Abstract:
LINK TO RESEARCH https://pubmed.ncbi.nlm.nih.gov/27914905/ ABSTRACT Aim: To assess the relationship between 25-hydroxyvitamin D [25(OH)D] blood concentrations in subjects with obesity and type 2 diabetes mellitus (T2D) risk according to the...

Diabetes Care in Venezuela

Published: Annals of Global Health
Date:
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Marcos Lima-Martínez 3 , Victoria Stepenka 4 , Alejandro Rísquez 5 , Jeffrey I Mechanick 6
Abstract:
The incidence of type 2 diabetes (T2D) and its economic burden have increased in Venezuela, posing difficult challenges in a country already in great turmoil.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

Published: International Journal of Obesity
Date:
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
Abstract:
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist

Published: The Journal of Pediatrics
Date:
Authors: R H Lustig 1 , S R Rose, G A Burghen, P Velasquez-Mieyer, D C Broome, K Smith, H Li, M M Hudson, R L Heideman, L E Kun
Abstract:
Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain.